<DOC>
	<DOC>NCT01522183</DOC>
	<brief_summary>Post-marketing safety data on patients treated and untreated with eculizumab.</brief_summary>
	<brief_title>Atypcial Hemolytic-Uremic Syndrome (aHUS) Registry</brief_title>
	<detailed_description>The study will capture post-marketing safety data on patients treated with eculizumab. Additionally, the study will collect information on the progression of disease in all patients.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Azotemia</mesh_term>
	<mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
	<mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
	<criteria>Male or female patients of any age, including minors, who have been diagnosed with aHUS Able to give written informed consent. Patient or patient's parent/legal guardian must be willing and able to given written informed consent and the patient (if minor) must be willing to give written informed assent [if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees (IRB/IEC)]. ADAMTS13 &gt; 5%, if performed. Hemolytic Uremic Syndrome (HUS) only due to Shiga Toxin</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Atypical Hemolytic-Uremic Syndrome</keyword>
	<keyword>aHUS</keyword>
	<keyword>Thrombotic Microangiopathy</keyword>
	<keyword>TMA</keyword>
</DOC>